contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bulletin-from-the-extraordinary-general-meeting-of-enzymatica-ab-publ-on-6-august-2024

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Enzymatica is a life science company that develops and sells medical devices for infection-related diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray which can prevent colds as well as shorten the illness period. The product has been launched on several markets and the strategy is to expand to more markets via partners. The company is headquartered in Lund. 

Enzymatica

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.The shareholders of Enzymatica...

<div class="abstract">The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.The shareholders of Enzymatica AB (publ) (the "Company") held an extraordinary general meeting on 6 August 2024. At the extraordinary general meeting, the following resolutions, amongst others, were made. &nbsp;</div>Approval of the board of directors' resolution on a rights issue of new sharesThe meeting resolved to approve the board of directors' resolution from 18 July 2024, to increase the Company's share capital by a maximum amount of SEK 2,774,117.32 through the issue of a maximum number of 69,352,888 shares.The shareholders of the Company shall have preferential rights to subscribe for the new shares in relation the number of shares previously held. For each share held on the record date, the shareholder receives one subscription right, whereby five (5) subscription rights entitle to subscribe for two (2) new shares.The record date for determining which shareholders shall be entitled to subscribe for new shares on a preferential basis shall be 26 August 2024.The subscription price is SEK 1.90 per share which in the case of full subscription provides issuing proceeds of up to approximately MSEK 131.8.Subscription for new shares by exercise of subscription rights shall be made by simultaneously cash payment during the period as from 28 August 2024 up to and including 11 September 2024. Subscription for new shares without the exercise of subscription rights shall take place during the same period on a separate subscription list. Payment for new shares subscribed for without the exercise of subscription rights shall be made in cash no later than on the second bank day from dispatch of the contract note setting forth the allotment of shares.Trading with subscription rights will take place during the period from 28 August 2024 until, and including 6 August 2024. Trading in BTA (Paid Subscribed Shares) will take place from 28 August 2024 until and including around 20 September 2024.&nbsp;For more detailed information regarding the content of the resolutions, please refer to the complete notice of the extraordinary general meeting and the Company's website, www.enzymatica.com.For more information, please contact:Claus Egstrand, CEO, Enzymatica AB Phone: +44 7780 22 8385 | Email:&nbsp;claus.egstrand@enzymatica.com

Bulletin from the extraordinary general meeting of Enzymatica AB (publ) on 6 August 2024

Stay up to date with our newsletter